Variable | Values (%)2 |
---|---|
Median Age in years (range) | 55 (32–77) |
Stage at Initial Diagnosis of Breast Cancer | |
I/II | 41 (59) |
III | 17 (24) |
IV | 12 (17) |
Hormone Receptor Status | |
ER and or PgR positive | 33 (47) |
ER and PgR Negative | 35 (50) |
ER and PgR Unknown | 2 (3) |
Exposure to anthracycline before the initial T-based regimen3 | 46 (66) |
Exposure to taxane before the initial T-based regimen3 | 18 (26) |
Prior Lines of Chemotherapy for Metastatic Disease4 | |
1 | 48 (68) |
2 | 10 (14) |
≥ 3 | 12 (17) |
Initial Trastuzumab-based regimen | |
Docetaxel 75–100 mg/m2 q3wks + T | 31 (44) |
Paclitaxel 80–90 mg/m2 weekly +T | 12 (17) |
Paclitaxel 175 mg/m2 q3wks + T | 5 (7) |
Vinorelbine 25–30 mg/m2 weekly + T | 4 (6) |
Docetaxel 75 mg/m2 + Epi-doxorubicin 75 mg/m2 q3wks + T | 4 (6) |
T alone | 4 (6) |
Other regimens | 7 (10) |
Unknown | 3 (4) |
Median Number of Metastatic Sites | 2 (1–6) |
Pattern of Metastatic Disease | |
Visceral (Liver + Lung) | 57 (81) |
Non Visceral/Non CNS (Bone, Soft Tissue, Effusions) | 11 (16) |
Central Nervous System (plus other sites) | 17 (24) |